Application of EndoScell Intraoperative Cellular Probing Technology for Early-Stage Breast Cancer

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorFudan University

About this trial

Sentinel Lymph Node Biopsy (SLNB) is a common surgical treatment for breast cancer and a primary method for assessing the pathological status of axillary lymph nodes. Precise intraoperative detection of sentinel lymph nodes during surgery assists in timely evaluation of axillary lymph node pathology and helps in formulating further treatment strategies.

Touch imprint cytology (TIC) is one of the most commonly used intraoperative detection techniques. The new intraoperative cellular detection technology, EndoScell Scanner (ES), uses an improved real-time miniaturized fluorescence microscopy system for image acquisition. The ultra-high-resolution images obtained can reach the cellular level. In previous studies, the accuracy and sensitivity of this technology for intraoperative detection of sentinel lymph nodes were comparable to imprint cytology, but it is much more rapid. The detection technology uses fluorescein sodium and methylene blue as fluorescent dyes, which is non-invasive and also non-consumptive of tissue samples.

This study involves patients scheduled for sentinel lymph node biopsy and aims to evaluate the clinical application value of the EndoScell Scanner (ES) for intraoperative assessment of the pathological status of sentinel lymph nodes through a prospective self-controlled study. To avoid the potential impact of methylene blue on the ES detection technology, we will use mitoxantrone as a new dye for sentinel lymph node tracing in this study.

The primary study objective is to compare the accuracy of the ES detection technology in assessing sentinel lymph node status, using paraffin pathology examination as the gold standard. The primary endpoint is the accuracy of the ES technology. Secondary endpoints include the image quality score of the ES detection, the learning curve of the surgeons, and the time required for detection.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18 years and older (inclusive)

Female

Preoperative pathology confirmed invasive breast carcinoma or ductal carcinoma in situ

Scheduled for sentinel lymph node biopsy

Disqualifiers

Patients with a confirmed allergy to methylene blue or sodium citrate tracers

Pregnant or lactating women

Patients unwilling to participate in the clinical study

Trial design

Design model

Single group

Treatments tested in this trial

  • EndoScell Scaner (ES) novel intraoperative cellular probing technology

    Procedure/Surgery

    In this project, we utilize the miniature wide-angle focusing microscope for intraoperative cell-level observation and detection, a technology in which our hospital has conducted extensive research and accumulated rich experience.

Treatment groups

709 Participants
are divided into 1 treatment group
Group A: Intraoperative AssessmentExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

The accuracy of ES technology

the accuracy of the ES technology (including accuracy, sensitivity and specificity)

Time frame
After the final pathological results are obtained, it is usually about 2 weeks after surgery
2

The reoperation rate

The proportion of reoperations due to a positive margin

Time frame
3 months after surgery

Secondary outcomes

1

The quality score of ES imaging

The image quality of ES was scored by the pathologist

Time frame
After the final pathological results are obtained, it is usually about 2 weeks after surgery
2

The learning curve of the surgeons

Evaluate the number of cases required for the surgeon to achieve 95% or more accuracy

Time frame
through study completion, an average of 1 year
3

The time required for the intraoperative evaluation

The time required for intraoperative detection using ES technology

Time frame
through study completion, an average of 1 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.